Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Neurol ; 90(5): 834-839, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34516013

RESUMO

The frequency of CD20+ T cells was reported to be increased in several inflammatory conditions. We report that in patients with multiple sclerosis (MS), CD20+ T cells display a distinct proinflammatory phenotype with pathogenic properties. Anti-CD20 treatment virtually extinguished CD20+ T cells, which might explain its broad effectiveness. Dimethyl fumarate dampened activity of differentiated CD20+ T cells, whereas fingolimod reduced their abundance only as part of its overall T cell suppressive capacity. Natalizumab increased the frequency of CD20+ effector T cells. Widely used MS therapeutics affect this proinflammatory T cell subset with assumed pathogenic potential in a surprisingly differential manner. ANN NEUROL 2021 ANN NEUROL 2021;90:834-839.


Assuntos
Antígenos CD20/efeitos dos fármacos , Esclerose Múltipla/tratamento farmacológico , Natalizumab/farmacologia , Subpopulações de Linfócitos T/efeitos dos fármacos , Fumarato de Dimetilo/farmacologia , Cloridrato de Fingolimode/farmacologia , Humanos , Esclerose Múltipla/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...